Director, Breast Pathology Fellowship

Conditions Treated:

Yong Hannah Wen, MD, PhD

About Me

As a board-certified pathologist with a specialization in breast pathology, I perform microscopic examination of breast biopsies and surgical specimens and make diagnoses that help guide treatment decisions for our patients. I am proud to be part of the multidisciplinary team providing breast cancer patients with comprehensive and coordinated care.

Read more

I am interested in the molecular and genetic mechanisms of breast cancer development, progression, and response to treatments. My current research is focused on triple negative breast carcinoma — a subgroup of breast cancer that does not express estrogen and progesterone receptors, or the human epidermal growth factor receptor 2 (HER2). I also work closely with my colleagues from surgery, medical oncology, and radiation oncology on a variety of clinical studies in breast cancer.

  • Clinical Expertise: Breast Pathology; Oncologic Pathology
  • Languages Spoken: English
  • Education: MD, Beijing Medical University (China); PhD, University of Texas MD Anderson Cancer Center
  • Residencies: NYU Medical Center
  • Fellowships: Memorial Sloan Kettering Cancer Center
  • Board Certifications: Anatomic Pathology; Clinical Pathology

New Patient Appointments

Making an appointment

Call 800-525-2225

See My Colleagues

Read more

Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O’Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O’Leary JJ.. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer 2009; 19 :641-647

Wen YH, Yee H, Goswami S, Shukla PS.. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Int J Gynecol Pathol 2009; 28 :187-192

Morris LG, Wen YH, Nonaka D, DeLacure MD, Kutler DI, Huan Y, Wang BY.. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck 2008; 30 :771-775

Rapkiewicz A, Wen H, Sen F, Das K.. Cytomorphologic examination of anaplastic large cell lymphoma by fine-needle aspiration cytology. Cancer 2007; 111 :499-507

Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncology report 2007; 18 :1387-1393

Wen YH, Giashuddin S, Shapiro RL, Velazquez E, Melamed J.. Unusual occurrence of a melanoma with intermixed epithelial component: a true melanocarcinoma?: case report and review of epithelial differentiation in melanoma by light microscopy and immunohistochemistry. American Journal of Dermatopathology 2007; 29 :395-399

Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, Eigenbrot C, Yee H, Steiner G, Greco MA.. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Human Pathol. 2007; 38 :1184-1191

Cha TL, Qiu L, Chen CT, Wen Y, Hung MC.. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Research 2005; 65 :2287-2295

Shao R, Lee DF, Wen Y, Ding Y, Xia W, Ping B, Yagita H, Spohn B, Hung MC. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Molecular Cancer Research 2005; 3 :219-226

Yan DH, Wen Y, Su LK, Xia W, Wang SC, Zhang S, Gan L, Lee DF, Spohn B, Frey JA, Hortobagyi GN, Hung MC.. A delayed chemically induced tumorigenesis in Brca2 mutant mice. Oncogene 2004; 23 :1986-1901

Deng J, Xia W, Miller SA, Wen Y, Wang HY, Hung MC.. Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol. Carcinogenesis 2004; 39 :139-146

Wen Y, Giri D, Yan DH, Spohn B, Zinner RG, Xia W, Thompson TC, Matusik RJ, Hung MC. Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol. Carcinogenesis 2003; 37 :130-137

Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC. Enhancement of Bik antitumor effect by Bik mutants. Cancer Research 2003; 63 :7630-7633

Yan DH, Abramian A, Li Z, Ding Y, Wen Y, Liu TJ, Hunt K.. P202, an interferon-inducible protein, inhibits E2F1-mediated apoptosis in prostate cancer cells. Biochemical and biophysical research communications 2003; 303 :219-222

Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, Hung MC.. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer.. Cancer Cell 2002; 2 :323-334

Ding Y, Wen Y, Spohn B, Wang L, Xia W, Kwong KY, Shao R, Li Z, Hortobagyi GN, Hung MC, Yan DH.. Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer.. Clinical Cancer Research 2002; 8 :3292-3297

Lee WP, Wen Y, Varnum B, Hung MC.. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 2002; 21 :329-336

Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, Hung MC.. Systemic tumor suppression by the proapoptotic gene bik. Cancer Research 2002; 62(1) :8-12

Wen Y, Yan DH, Wang B, Spohn B, Ding Y, Shao R, Zou Y, Xie K, Hung MC.. p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Research 2001; 61(19) :7142-7147

Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC.. Nuclear localization of EGF receptor and its potential new role as a transcription factor.. Nature Cell Biology 2001; 3 :802-808

Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC.. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Research 2000; 60 :68410845

Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC.. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.. Proceedings of the National Academy of Sciences USA 2000; 97 :4262-4266

Wen Y, Yan DH, Spohn B, Deng J, Lin SY, Hung MC.. Tumor suppression and sensitization to tumor necrosis factor alpha-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. Cancer Research 2000; 60 :42-46

Yan DH, Wen Y, Spohn B, Choubey D, Gutterman, JU, and Hung, MC. Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. Oncogene 1999; 18 :807-811

Wen Y and Liu B.. The expression of transforming growth factor alpha in the mouse embryos and preimplantation uterus. J. Beijing Medical University 1997; 29 :12-14

Wen Y and Liu B.. Transforming growth factor alpha and its receptor in reproduction process. (in Chinese). Foreign Medical Sciences 1997; 16 :27-30

Wen Y and Liu B. . The role of platelet activating factor in reproduction (in Chinese). Progress of Anatomical Sciences 1996; 2 :204-211


Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more